Integra Lifesciences (NASDAQ:IART) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, December 26th.
According to Zacks, “Integra LifeSciences' contracting adjusted operating margin and adjusted gross margin have been causing troubles for the company of late. Also the company’s decision to sell its certain neurosurgery assets to Natus Medical may hamper its business in near term. However, the strong year-over-year increase in revenues on the back of strong growth within Orthopedics and Tissue Technologies segment buoys optimism. Raised full-year revenue guidance is indicative of this bullish trend to remain. We are happy with the fact that, the company is efficiently executing its growth plan through an efficient management team. However, the slashed full-year adjusted earnings range remains a concern. Overall, over the past year, Integra Lifesciences has been trading above the broader industry.”
Several other equities research analysts also recently issued reports on IART. Jefferies Group reissued a “buy” rating and issued a $58.00 price objective on shares of Integra Lifesciences in a research note on Thursday, October 12th. Oppenheimer reissued a “buy” rating on shares of Integra Lifesciences in a research note on Thursday, October 26th. UBS Group reissued a “buy” rating and issued a $57.00 price objective on shares of Integra Lifesciences in a research note on Tuesday, October 31st. JPMorgan Chase & Co. downgraded Integra Lifesciences from an “overweight” rating to a “neutral” rating and set a $44.00 price objective for the company. in a research note on Friday, October 27th. Finally, TheStreet downgraded Integra Lifesciences from a “b” rating to a “c+” rating in a research note on Thursday, October 26th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $52.70.
Shares of Integra Lifesciences (IART) opened at $50.57 on Tuesday. The company has a market capitalization of $3,960.76, a price-to-earnings ratio of 82.90, a PEG ratio of 1.68 and a beta of 0.65. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26. Integra Lifesciences has a fifty-two week low of $40.51 and a fifty-two week high of $56.42.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.02). The business had revenue of $278.83 million during the quarter, compared to analysts’ expectations of $286.00 million. Integra Lifesciences had a return on equity of 16.35% and a net margin of 4.52%. The firm’s revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.93 earnings per share. sell-side analysts anticipate that Integra Lifesciences will post 1.85 EPS for the current year.
In other Integra Lifesciences news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares of the company’s stock, valued at approximately $1,022,371.35. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Barbara B. Hill acquired 10,768 shares of the stock in a transaction dated Tuesday, October 31st. The shares were bought at an average cost of $46.66 per share, for a total transaction of $502,434.88. Following the acquisition, the director now owns 55,540 shares in the company, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. Corporate insiders own 21.50% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP increased its holdings in shares of Integra Lifesciences by 213.1% during the 3rd quarter. GSA Capital Partners LLP now owns 28,249 shares of the life sciences company’s stock valued at $1,426,000 after acquiring an additional 19,226 shares during the last quarter. California Public Employees Retirement System increased its holdings in shares of Integra Lifesciences by 6.8% during the 3rd quarter. California Public Employees Retirement System now owns 132,002 shares of the life sciences company’s stock valued at $6,663,000 after acquiring an additional 8,402 shares during the last quarter. Zions Bancorporation acquired a new position in shares of Integra Lifesciences during the 3rd quarter valued at about $205,000. Orbimed Advisors LLC increased its holdings in shares of Integra Lifesciences by 155.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,090,910 shares of the life sciences company’s stock valued at $55,069,000 after acquiring an additional 664,000 shares during the last quarter. Finally, Segall Bryant & Hamill LLC increased its holdings in shares of Integra Lifesciences by 20.9% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 112,520 shares of the life sciences company’s stock valued at $5,680,000 after acquiring an additional 19,486 shares during the last quarter. 87.58% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.thelincolnianonline.com/2018/01/14/integra-lifesciences-iart-upgraded-by-zacks-investment-research-to-hold-updated-updated.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.